M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Investigating the Effect of Simulated Live Piano Music on Preoperative Cancer Patients, Health Care Providers and Hospital Volunteers Using Validated Questionnaires and Proteomic Analysis

Withdrawn

Conditions: Abdominal Cancer Patients
Symptoms and Signs Involving Cognition Perception Emotion & Behaviour

Interventions: Procedure: Blood Draws
Behavioral: Musical Intervention
Behavioral: Questionnaires

First Posted Date: 2017-08-04

Last Posted Date: 2023-08-14

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03239587

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Withdrawn

Conditions: CCND1 Positive
CD20-Positive Neoplastic Cells Present
Mantle Cell Lymphoma

Interventions: Drug: Dexamethasone
Drug: Ibrutinib
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2017-07-27

Last Posted Date: 2019-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03232307

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

Phase 2

Active, not recruiting

Conditions: Oropharyngeal Cancer
Malignant Neoplasms of Lip Oral Cavity and Pharynx

Interventions: Procedure: Modified Barium Swallow (MBS)
Behavioral: Swallowing Questionnaire
Behavioral: Symptom Questionnaire
Procedure: Video-Strobe Procedure
Procedure: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning
Procedure: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning
Radiation: Intensity Modulated Radiotherapy (IMRT)

First Posted Date: 2017-07-21

Last Posted Date: 2025-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT03224000

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Phase 1

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IIIC Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma

Interventions: Biological: Pembrolizumab
Other: Pharmacokinetic Study
Drug: Trametinib

First Posted Date: 2017-07-21

Last Posted Date: 2025-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT03225664

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Resectable Hepatocellular Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2017-07-19

Last Posted Date: 2023-07-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03222076

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Early Phase 1

Completed

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions: Other: Best Practice
Drug: Ibrutinib
Other: Personalized Medicine
Other: Patient Derived Xenograft

First Posted Date: 2017-07-17

Last Posted Date: 2023-07-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT03219047

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

Not Applicable

Active, not recruiting

Conditions: Neuropathy
Malignant Neoplasm

Interventions: Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Repetitive Transcranial Magnetic Stimulation
Procedure: Sham Intervention

First Posted Date: 2017-07-17

Last Posted Date: 2025-04-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT03219502

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Castration-Resistant Prostate Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Metastatic Prostate Carcinoma
Prostate Carcinoma Metastatic in the Bone
Refractory Malignant Solid Neoplasm
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8

Interventions: Drug: Avelumab
Biological: Ivuxolimab
Radiation: Radiation Therapy
Biological: Utomilumab

First Posted Date: 2017-07-14

Last Posted Date: 2025-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 173

Registration Number: NCT03217747

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine
Drug: Idarubicin
Biological: Pegfilgrastim
Drug: Venetoclax

First Posted Date: 2017-07-11

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT03214562

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery

Phase 3

Recruiting

Conditions: Liver and Intrahepatic Bile Duct Disorder

Interventions: Drug: Bupivacaine
Drug: Fentanyl
Drug: Liposomal Bupivacaine
Drug: Hydromorphone Hydrochloride
Device: Implanted Medical Device
Behavioral: Questionnaire

First Posted Date: 2017-07-11

Last Posted Date: 2025-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT03214510

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy